Numbers of patients with actinic keratosis lesions who were randomized to treatment with topical 0.5% fluorouracil or vehicle before cryosurgeryand evaluated at 4-month and 6-month follow-up visits.
Joseph Jorizzo, Jonathan Weiss, Katharine Furst, Christine VandePol, Sharon F. Levy. Effect of a 1-Week Treatment With 0.5% Topical Fluorouracil on Occurrence of Actinic Keratosis After CryosurgeryA Randomized, Vehicle-Controlled Clinical Trial. Arch Dermatol. 2004;140(7):813–816. doi:10.1001/archderm.140.7.813
No long-term randomized controlled clinical trial has compared the efficacy of cryosurgery alone vs cryosurgery following fluorouracil applications forthe treatment of actinic keratosis.
To determine the 6-month outcome of a 1-week course of 0.5% fluorouracil followed by cryosurgery.
Prospective, multicenter, randomized, double-blind, vehicle-controlled clinical trial performed in community and academic outpatient clinics.
A total of 144 patients with 5 or more visible or palpable actinic keratoses on the face.
Topical 0.5% fluorouracil or vehicle once daily for 7 days. At the 4-week follow-up visit, residual lesions were treated with cryosurgery.
Main Outcome Measure
Reduction in facial actinic keratoses from baseline to 4 weeks and 6 months.
At 4 weeks, mean actinic keratosis lesion count was reduced by 62.4% in the 0.5% fluorouracil group vs 28.8% in the vehicle group (P<.001), and complete clearance was achieved in 16.7% of patientsin the 0.5% fluorouracil group vs 0% of those in the vehicle group (P<.001). At 6 months, mean lesion count was reducedby 67.0% in the 0.5% fluorouracil plus cryosurgery group vs 45.6% in the vehicleplus cryosurgery group (P = .01), and significantly more patients in the 0.5% fluorouracil plus cryosurgery group than in thevehicle plus cryosurgery group had complete clearance (30% vs 7.7%; P<.001).
A 1-week course of topical 0.5% fluorouracil before cryosurgery is significantly more effective in reducing patients' numbers of actinic keratosis lesions6 months after treatment than cryosurgery alone. The high occurrence rate of actinic keratosis lesions at 6 months suggests a need for follow-up.
More than 1 million new cases of skin cancer will be diagnosed in the United States and an estimated 9800 individuals will die from skin cancerthis year.1Actinic keratosis (AK) skin lesions have an estimated 10% rate of progression to invasive squamouscell carcinoma.2- 4 Because AK has the potential to evolve into an aggressive disease, treatment of allAK lesions has been recommended.5,6
Effective treatments for AK lesions include chemical destruction by topical medications such as 5-fluorouracil or physical destruction by cryosurgery,curettage, electrosurgery, and in some cases, excision or dermabrasion.7- 9 The most commonly used treatment modality in the United States is cryosurgery with liquid nitrogen.6,9 Fluorouracil is an antineoplastic antimetabolitethat has been known for approximately 40 years to have beneficial effects on AK lesions.10,11 Clinical trialshave repeatedly found topical fluorouracil to be effective for the treatment of AK lesions when applied in concentrations of 0.5%, 1%, and 5%.12- 16
The long-term outcomes of cryosurgery and the effect of a regimen using topical fluorouracil before cryosurgery have not been evaluated in randomizedor controlled trials. A 1-week course of topical 0.5% fluorouracil is effective and well tolerated in the treatment of AK.17,18 Thepresent study evaluates whether pretreatment with a 1-week course of 0.5% fluorouracil before cryosurgery would provide greater long-term efficacy inpreventing occurrence of AK lesions than cryosurgery alone.
Eligible patients were 18 years or older and had 5 or more visible orpalpable AK lesions on the face. Women were eligible if they were postmenopausalor using appropriate contraceptive methods and not pregnant or lactating. Patients were excluded if they had basal or squamous cell carcinomas, otherpotentially confounding skin conditions, or known allergies to ingredients of the test drug formulation; or if they had been treated for AK lesions withtopical medications within the 5 previous months, had cryosurgery within the previous 4 weeks, or were engaged in activities that involved excessive orprolonged exposure to sunlight. Patient recruitment took place from October 2001 to February 2002.
This is a 12-month, multicenter, randomized, double-blind,vehicle-controlled clinical trial with a preplanned 6-month interim analysis(presented in this report) after completion of the first cycle of treatment. The study was performed in community and academic outpatient clinics.Eligible patients were randomly assigned in a 1:1 ratio at baseline (day 1)to apply topical 0.5% fluorouracil cream (Carac; Dermik Laboratories, Berwyn,Pa) or vehicle cream once daily for 7 days to the face plus 1 or more of thefollowing investigator-designated areas: scalp, ears, neck, and/or lips (defined at screening as the treatment area). Eligible patients at each site were assignedby the investigator the next available (ie, lowest available) treatment allocation number from a computer-generated randomization schedule. All study personnel,investigators, and patients were blinded to actual treatment assignment. The fluorouracil and vehicle creams, which were indistinguishable in texture,color, and smell, were supplied in identical tubes, patient kits, and labeling.
Any residual AK lesions in the treatment area were treated after the 4-week assessment with liquid nitrogen cryosurgery as a single spray of 1to 2 seconds with a Cryac device (Brymill Inc, Vernon, Conn), with a resultant mean thaw time of about 10 seconds. Patients then returned for follow-up 6months (± 2 weeks) after initial topical treatment.
The study protocol was approved by institutional review boards at all participating institutions, and written informed consent was obtained fromall patients before study enrollment.
Efficacy variables were the numbers of facial AK lesions, the proportion of patients with complete clearance of AK lesions, and the occurrence (ie,presence) rate of AK lesions. The same evaluator counted visible and/or palpable AK lesions before initial treatment and at the 4-week and 6-month follow-upvisits.
Severe application site reactions (erythema, edema, dryness, pain, erosion, burning, and pruritus) and eye irritation (burning, sensitivity, itching,stinging, and watering) were recorded at each visit, as were any other adverse events.
A sample size of 70 patients per treatment group was calculated to provide greater than 90% power to detect a difference in clearance rates at 4 weeks,based on the assumption of a 20% clearance in the fluorouracil group and a 3% clearance in the vehicle group. Assuming a standard deviation of 25% anda dropout rate of 25% by 6 months, this sample size would also provide greater than 80% power to detect a significant difference (at the .025 level to adjustfor multiple analyses) in occurrence at 6 months between the fluorouracil and vehicle groups.
The primary efficacy end points were the reduction (absolute and percentage) in AK lesions at the 4-week follow-up visit, the proportion of patients withcomplete clearance of AK lesions at the 4-week follow-up visit (before cryosurgery), and the occurrence rate at the 6-month follow-up visit. The clearance rateat 6 months was also determined.
Efficacy analyses were performed for all patients of this intent-to-treat study who had at least 1 postbaseline efficacy measurement. Between-groupcomparisons for AK lesion counts and percentage reduction of AK lesions were performed using a Wilcoxon rank sum test. A Mantel-Haenszel χ2 testwas used to compare the proportion of patients in each group with total clearance of AK lesions at the 4-week and 6-month follow-up visits. Occurrence at 6months was analyzed by comparison of the number of AK lesions and the percentage reduction in AK lesions using a Wilcoxon rank sum test. Changes from baselinewithin a treatment group were analyzed using a paired t test.
Statistical outcomes for the between-group comparisons at 4 weeks were considered significant with P<.05. For the between-groupcomparison of occurrence rates at 6 months, the analysis was considered significant with P<.025.
Of the 144 patients enrolled in the study, 72 were randomly assignedto receive topical 0.5% fluorouracil and 72 to receive vehicle (Figure 1), and 142 were included in the intent-to-treat study population.Of these, 1 patient who did not return for follow-up and 1 who withdrew consent prior to treatment were not included in the efficacy analyses. The 143 patientswho received any study treatment were included in the safety analyses. There were no important differences in patient demographics or baseline characteristicsbetween treatment groups (Table 1).
At 4 weeks, patients treated with topical 0.5% fluorouracil cream once daily had significantly fewer AK lesions on the face than thosein the vehicle group (4.3 vs 9.1, respectively; P<.001). Both the absolute and percentage reduction in AK lesions from baseline were significantly greater in the topical 0.5% fluorouracil group than inthe vehicle group (P<.001) (Table 2). The proportion of patients with complete clearance offacial AK lesions at 4 weeks was 16.7% in the topical 0.5% fluorouracil groupand 0% in the vehicle group (P<.001) (Table 2). Patients with residual lesions at the 4-week follow-up visit received cryosurgery to remove all remaininglesions.
Six months after the initial treatment, 30% of patients in the topical 0.5% fluorouracil plus cryosurgery group were clear of facialAK lesions compared with 7.7% of patients in the vehicle plus cryosurgerygroup (P<.001). The mean number of AKlesions present was significantly less and the percentage reduction significantly greater (P = .01 for both end points) for patientsin the topical 0.5% fluorouracil plus cryosurgery group than for patients in the vehicle plus cryosurgery group (Table 2), although the mean absolute change from baseline was notsignificantly different. Of the 12 patients in the topical 0.5% fluorouracil treatment group who were clear of AK lesions at the 4-week follow-up visit(and therefore did not require cryosurgery), 11 had an assessment at 6 months.Five of the 11 patients remained clear at 6 months.
Eye irritation occurred in as many patients in the vehicle group (10 [14%]) as in the topical 0.5% fluorouracil group (10 [14%]) and was ratedas mild for all but 1 patient in the fluorouracil group who had moderately severe irritation. Application site reactions were reported in 13 patients(18%) in the topical 0.5% fluorouracil group and in 3 patients (4%) in the vehicle group (P = .02). No patient discontinuationswere due to adverse events.
The results of this study indicate a need to evaluate patients 6 months after treatment for AK lesions, especially if cryosurgeryalone is used. More than 90% of patients who had cryosurgery but did not receive pretreatment with 0.5% fluorouracil had lesions at 6 months. Treatmentwith topical 0.5% fluorouracil before cryosurgery significantly reduced the proportion of patients with AK lesions compared with patients receiving cryosurgeryalone, and thus reduced the need for retreatment during long-term follow-up.
The initial 4-week treatment results confirmed the finding of other controlled trials that topical 0.5% fluorouracil is effective in reducingAK lesions when used once daily for 1 week.17,18 The clearance rates of 16.7% and 0% (fluorouracil vs vehicle) at 4 weeks wereclose to the assumed rates of 20% and 3% used in determining statistical power of the study. The power of the study is therefore adequate to support theconclusion that a 1-week course of 0.5% fluorouracil is significantly moreeffective than vehicle.
The results at 6 months demonstrate that a short course of topical fluorouracil before cryosurgery significantly improves long-term outcomes. These resultswere achieved even though the statistical analysis was adjusted to account for the fact that this was an interim analysis. One possible explanation forthis improvement in long-term efficacy may be that subclinical AK lesions may have become clinically evident after fluorouracil treatment, allowingearlier removal with cryosurgery. Fluorouracil also may have successfully treated incipient lesions, thus preventing their progression.
Although it is commonly accepted that cryosurgery eradicates AK lesions, we could find no randomized or controlled prospective trials in the literaturethat studied longer-term outcomes of cryosurgery for AK. An open observational study found a long-term cure rate of 98.8% with cryosurgery, based on 12 recurrencesof 1018 treated lesions in 70 patients.9 It was not stated if patients in this study received other treatment at any timeor if new lesions occurred. Because of the differences in study design, no comparison can be made with the results of the current study, which founda higher incidence of AK lesions at 6 months.
Only anecdotal evidence of sequential use of topical fluorouracil and cryosurgery in treatment of AK lesions has previously been reported.19 Abadir20 describeda method in which patients were treated with topical 5% fluorouracil twice daily for 10 days, after which areas showing actinic damage were sprayed withliquid nitrogen. Although the method was described as successful, no quantitative outcomes were provided. The present study provides quantitative support forthe use of topical fluorouracil and cryosurgery for the treatment of AK lesionsand suggests that this novel approach can reduce the occurrence of new lesions.Although most patients are treated intermittently with cryosurgery, they maintain a high number of lesions. Interval therapy for 1 week with topical fluorouracilmay therefore reduce the number of lesions requiring cryosurgery.
In conclusion, the results of our study support the need for a 6-month follow-up visit for patients treated for AK lesions. Most patients will havelesions again within 6 months of receiving cryosurgery for multiple AK lesions. A 1-week course of topical 0.5% fluorouracil before cryosurgery significantlyincreases the proportion of patients who are clear of facial AK lesions at6 months, thus reducing the need for retreatment.
Correspondence: Joseph Jorizzo, MD, Clinical Sciences Bldg, Ninth Floor, Department of Dermatology, Wake Forest University School of Medicine,Medical Center Bldg, Winston-Salem, NC 27157-1071.
Accepted for publication January 2, 2004.
This study was supported by a grant from Dermik Laboratories.
We thank the following investigators who participated in the clinical trial: Alicia Bucko, DO, Albuquerque, NM; Steven M. Davis, MD, San Antonio,Tex; Alan Menter, MD, Dallas, Tex; Toivo Rist, MD, Knoxville, Tenn; Joel S. Shavin, MD, Snellville, Ga; and Daniel Stewart, DO, Clinton Township, Mich.